- Home
- RNTX vs FCO Comparison
RNTX vs FCO Comparison
Compare RNTX & FCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNTX
- FCO
- Stock Information
- Founded
- RNTX 2001
- FCO 1991
- Country
- RNTX United States
- FCO United Kingdom
- Employees
- RNTX N/A
- FCO N/A
- Industry
- RNTX Biotechnology: Pharmaceutical Preparations
- FCO Investment Managers
- Sector
- RNTX Health Care
- FCO Finance
- Exchange
- RNTX Nasdaq
- FCO Nasdaq
- Market Cap
- RNTX 34.6M
- FCO 40.5M
- IPO Year
- RNTX N/A
- FCO N/A
- Fundamental
- Price
- RNTX $1.25
- FCO $3.04
- Analyst Decision
- RNTX Buy
- FCO
- Analyst Count
- RNTX 2
- FCO 0
- Target Price
- RNTX $10.00
- FCO N/A
- AVG Volume (30 Days)
- RNTX 2.6M
- FCO 100.1K
- Earning Date
- RNTX 11-14-2025
- FCO 01-01-0001
- Dividend Yield
- RNTX N/A
- FCO 14.96%
- EPS Growth
- RNTX N/A
- FCO N/A
- EPS
- RNTX N/A
- FCO 0.43
- Revenue
- RNTX N/A
- FCO N/A
- Revenue This Year
- RNTX N/A
- FCO N/A
- Revenue Next Year
- RNTX N/A
- FCO N/A
- P/E Ratio
- RNTX N/A
- FCO $12.30
- Revenue Growth
- RNTX N/A
- FCO N/A
- 52 Week Low
- RNTX $1.04
- FCO $4.73
- 52 Week High
- RNTX $3.50
- FCO $6.63
- Technical
- Relative Strength Index (RSI)
- RNTX 44.48
- FCO 46.33
- Support Level
- RNTX $1.15
- FCO $2.96
- Resistance Level
- RNTX $1.32
- FCO $3.06
- Average True Range (ATR)
- RNTX 0.20
- FCO 0.07
- MACD
- RNTX -0.04
- FCO 0.05
- Stochastic Oscillator
- RNTX 11.65
- FCO 77.27
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
About FCO abrdn Global Income Fund Inc.
abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets and Sub-Investment Grade Developing Markets.